Hepatotoxicity and Gastrointestinal Intolerance when Healthy Volunteers taking Rifampin add Twice-Daily Atazanavir and Ritonavir

BACKGROUND: Rifampin is the cornerstone of antituberculosis therapy, but induction of hepatic cytochrome P450 (CYP) 3A by rifampin markedly lowers HIV protease inhibitor plasma concentrations. METHODS: This phase I, open-label, one-arm study was designed to assess pharmacokinetic interactions and sa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Haas, David W., Koletar, Susan L., Laughlin, Laura, Kendall, Michelle A., Suckow, Carol, Gerber, John G., Zolopa, Andrew R., Bertz, Richard, Child, Michael J., Hosey, Lara, Alston-Smith, Beverly, Acosta, Edward P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2653210/
https://ncbi.nlm.nih.gov/pubmed/19194314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e318189a7df
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak